McMaster University

Medical Sciences
Graduate Program

Scope of Search

Mark Tarnopolsky

Mark Tarnopolsky


Research Interests

The overall theme of our research is an evaluation of treatment strategies to attenuate the effect of neuromuscular disorders and aging on skeletal muscle function.

Currently, we are looking at a number of nutritional and exercise interventions to enhance muscle function in response to neuromuscular, neurometabolic disorders as well as in the aging process. We have transgenic animal models of several neuromuscular disorders and are also completing clinical trials in patients with these conditions. Another line of research is the role of mitochondria in aging and the role of oxidative stress/apoptosis in skeletal muscle damage in response to exercise and neuromuscular disorders.

We use a variety of methods in the laboratory from strength and functional outcome measures in the dry laboratory to Western blotting, RT-PCR, PCR, enzyme analysis, metabolite analysis, ELISA, microscopy (immuno, EM and fluorescent methods), GC-MS, micro array, HPLC and RIA.


McMaster University
Health Sciences Centre

telephone: (905) 521-2100 ext. 75226

Program Area

Metabolism & Nutrition

Research Focus

Mitochondria, Estradiol, Muscle Damage, Apoptosis, Inflammation, Skeletal, Muscle, Exercise, Neuromuscular Disorders, Aging, Corticosteroids

Selected Publications

  • Three minutes of all-out intermittent exercise per week increases skeletal muscle oxidative capacity and improves cardiometabolic health. Gillen JB, Percival ME, Skelly LE, Martin BJ, Tan RB, Tarnopolsky MA, Gibala MJ. PLoS One. 2014 Nov 3;9(11):e111489. doi: 10.1371/journal.pone.0111489. eCollection 2014.
  • The Order of Exercise during Concurrent Training for Rehabilitation Does Not Alter Acute Genetic Expression, Mitochondrial Enzyme Activity or Improvements in Muscle Function.

    MacNeil LG, Glover E, Bergstra TG, Safdar A, Tarnopolsky MA. PLoS One. 2014 Oct 7;9(10):e109189. doi: 10.1371/journal.pone.0109189. eCollection 2014.

  • Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial. Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F. Ann Neurol. 2014 Oct;76(4):509-21. doi: 10.1002/ana.24248. Epub 2014 Aug 30.